Larazotide: A Literature Course on a Tight Junction Peptide

About this course

This course summarises what the published literature reports about larazotide, also written as larazotide acetate and labelled AT-1001 in preclinical papers. The compound has been described as a synthetic peptide that acts on intestinal tight junctions. Each of the six modules below closes with an explicit statement of the limits of the evidence, because much of the larazotide record sits in early-phase trials, animal models and cell culture. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, symptoms or treatment. Nothing below is a protocol, a recommendation or a statement of benefit.

Module 1: What larazotide is and how it has been studied

Definition and class. Larazotide acetate is described in the literature as a small synthetic peptide developed as a tight junction regulator, a class of agents intended to act on the paracellular barrier between intestinal epithelial cells rather than on an immune target (PMID 33881350). A 2021 review referred to the same molecule as the zonulin inhibitor AT-1001 and catalogued its investigation across a range of acute and chronic inflammatory conditions (PMID 33397225).

Origin. Reviews of the compound describe larazotide as a peptide modelled on a region of the Vibrio cholerae zonula occludens toxin, the bacterial protein whose barrier-opening activity led to the zonulin concept in gut permeability research (PMID 33881350). A celiac-focused review placed the peptide in the same lineage and framed tight junction regulation as the rationale for testing it in gluten-related disease (PMID 26770266).

Forms used in research. The forms differ by study type. Human celiac disease trials used an orally administered formulation given three times daily (PMID 25683116). Laboratory work has applied the peptide directly to epithelial cell monolayers and to intestinal tissue (PMID 22401908). A 2025 paper described an antibacterial hyaluronic acid hydrogel engineered for sustained release of larazotide and tested as a colitis treatment in an experimental model (PMID 40915363). A separate 2025 study applied larazotide to keratinocytes in a skin-barrier experiment rather than to gut tissue (PMID 40330848).

Limits of the evidence (Module 1)

The descriptive record is consistent on class and origin, but the formulations tested are not interchangeable: an oral capsule in a celiac trial, a hydrogel in a rodent colitis model and a peptide added to cultured keratinocytes are three different experiments. No published comparison in the verified literature establishes equivalence between these delivery forms.

Module 2: Mechanism as described in the literature

The mechanism most often attributed to larazotide is regulation of epithelial tight junctions. A 2012 study reported that larazotide acetate regulated epithelial tight junctions in both in vitro monolayers and in vivo models, and framed the peptide as acting on the assembly and integrity of junctional structures rather than as an antibiotic or immunosuppressant (PMID 22401908). A 2021 physiology review described the pharmacological logic in more detail, presenting larazotide as a peptide approach to tight junction regulation that interferes with the signalling cascade linked to barrier opening (PMID 33881350).

In the celiac literature, the mechanistic proposal was that gluten-associated increases in paracellular permeability could be limited at the epithelial barrier, upstream of the downstream immune response; researchers described this as a rationale for testing tight junction regulation as an adjunct to dietary management (PMID 26770266). The zonulin-inhibitor framing in a 2021 medicinal chemistry review extended the same reasoning to other inflammatory states in which barrier leak has been proposed as a contributor (PMID 33397225).

A newer mechanistic strand describes receptor-level activity. A 2025 study characterised larazotide as a PAR2 antagonist and reported that it mitigated acute histamine-stimulated epithelial barrier disruption in keratinocytes, discussed by the authors as a potential adjunct concept for atopic dermatitis (PMID 40330848).

Limits of the evidence (Module 2)

Mechanistic statements come largely from cell systems, tissue preparations and review synthesis. The zonulin pathway itself remains an area of ongoing debate in barrier physiology, and the verified papers do not provide a single receptor-level mechanism that has been confirmed across all the models in which the peptide was tested.

Module 3: Reported outcomes by study

Human randomized trials in celiac disease

A 2015 randomized controlled trial studied adults who had persistent symptoms of celiac disease despite a gluten-free diet; researchers assigned larazotide acetate at 0.5 mg, 1 mg or 2 mg three times daily against placebo and reported that the 0.5 mg dose was associated with a reduction in symptom scores while the higher doses were not (PMID 25683116). A 2013 randomized, placebo-controlled study examined larazotide acetate in patients with coeliac disease undergoing a supervised gluten challenge and reported measures of intestinal permeability, antibody response and symptoms across dose groups (PMID 23163616).

A 2022 systematic review and meta-analysis pooled randomized controlled trials of larazotide acetate in celiac disease and reported that the lowest dose studied, 0.5 mg three times daily, was the dose most consistently associated with symptom improvement across the pooled data, while permeability endpoints were less consistent (PMID 34339872). The non-linear dose pattern — a lower dose performing better than higher doses — was noted in review discussion of the same trial programme (PMID 26770266).

Preclinical and translational models

Pediatric post-COVID multisystem inflammatory syndrome

A 2025 translational study in children with post-COVID multisystem inflammatory syndrome reported clearance of viral spike antigen and augmented clinical recovery in those treated with larazotide compared with the comparison group described by the authors (PMID 40737433). The 2021 zonulin-inhibitor review had earlier grouped this kind of barrier-leak hypothesis under a broader set of acute and chronic inflammatory indications proposed for AT-1001 (PMID 33397225).

Limits of the evidence (Module 3)

Reported outcomes are endpoint-specific and model-specific. Symptom scores, permeability ratios, histology and antigen clearance are different measurements, and improvement on one does not establish improvement on another. The celiac programme's inverse dose pattern remains unexplained in the verified literature, no verified paper reports an approved indication or a completed confirmatory phase 3 outcome, and animal and cell findings do not transfer automatically to people.

Module 4: Larazotide Side Effects: What Studies Report

Adverse events in the larazotide literature are reported mainly within the celiac disease trial programme. The 2015 randomized controlled trial in adults with persistent symptoms despite a gluten-free diet collected safety data alongside its symptom endpoints across the 0.5 mg, 1 mg and 2 mg three-times-daily arms and placebo, and the trial report presented adverse events as part of that assessment (PMID 25683116). The 2013 gluten-challenge study similarly monitored adverse events during the challenge period alongside permeability and symptom measures (PMID 23163616).

The 2022 systematic review and meta-analysis of randomized controlled trials assessed safety as well as efficacy across the pooled celiac trials and reported that larazotide acetate was described as generally tolerated at the doses studied (PMID 34339872). Reviews of the compound have linked that tolerability profile to its proposed site of action: because the peptide is described as working locally at the intestinal epithelium rather than systemically, reviewers discussed a correspondingly local exposure pattern (PMID 33881350). A celiac-focused review made the same point when discussing why tight junction regulation was pursued as an adjunct strategy (PMID 26770266).

In the pediatric setting, the 2025 study in children with post-COVID multisystem inflammatory syndrome reported clinical course and recovery alongside antigen clearance in treated children, within a small, defined patient group (PMID 40737433).

Limits of the evidence (Module 4)

Safety conclusions here are narrow. Trial-level adverse event tables appear in full-text reports rather than in the summary record, event counts in early-phase trials are small, exposure durations were short, and no verified paper reports long-term safety, use in pregnancy, pediatric chronic dosing, or interactions with other medicines. Absence of reported harm in a short trial is not evidence of long-term safety, and adverse events observed in non-oral or hydrogel formulations were not studied in people.

Module 5: Pharmacokinetics where data exist

The verified literature describes larazotide's pharmacology primarily in terms of local action at the epithelial surface rather than a conventional systemic pharmacokinetic profile. The 2021 physiology review presented the peptide as a pharmacological agent acting on tight junctions at the site of administration, which is the framing used to explain why oral dosing was chosen in the clinical programme (PMID 33881350). A celiac review similarly discussed luminal activity at the intestinal epithelium as central to the therapeutic concept (PMID 26770266).

Dosing schedules in the human trials give an indirect picture of exposure assumptions: the 2015 trial used three-times-daily oral administration of 0.5 mg, 1 mg or 2 mg, consistent with a short-acting, locally acting agent given with meals (PMID 25683116). Formulation research has tried to alter that exposure pattern: the 2025 study built a hyaluronic acid hydrogel to provide sustained release of larazotide in a colitis model rather than repeated bolus dosing (PMID 40915363).

Limits of the evidence (Module 5)

No verified paper in this set reports human plasma concentrations, half-life, bioavailability, metabolic pathway or renal handling for larazotide. Statements about local action are mechanistic descriptions drawn from reviews, not measured pharmacokinetic parameters, and sustained-release behaviour demonstrated in a hydrogel model says nothing about the oral formulations used in trials.

Module 6: Regulatory status, stated factually

Approved products. Across the verified literature, larazotide acetate is presented as an investigational agent studied in randomized trials rather than as a marketed medicine; the 2022 meta-analysis pooled randomized controlled trials precisely because the compound's efficacy question remained open at the time of publication (PMID 34339872). Reviews of tight junction regulation in celiac disease likewise described it as a candidate strategy under evaluation rather than an approved adjunct to the gluten-free diet (PMID 26770266). No verified paper describes an approved larazotide product for any indication.

Research-use-only material. Peptides supplied for laboratory work are labelled research use only, which means they are intended for in vitro or animal experiments and are not regulated as drugs for human administration. The preclinical papers in this course reflect that category: cell monolayers, porcine tissue, rat models and hydrogel systems (PMID 22401908, PMID 33886649).

Compounding. In the United States, a bulk drug substance generally must appear in an applicable FDA list, have a USP or NF monograph, or be a component of an FDA-approved drug to be eligible for pharmacy compounding under the relevant sections of the Federal Food, Drug, and Cosmetic Act. A peptide with no approved product and no monograph does not meet those criteria by default. Investigational use in trials occurs under an investigational new drug pathway, which is distinct from compounding. This is general regulatory information and not legal advice.

Limits of the evidence (Module 6)

Regulatory status changes over time and by jurisdiction, and the verified papers were published at specific moments in the development programme. They do not document current agency decisions, designations, discontinuations or filings, and nothing in this module should be read as a description of present-day legal availability anywhere.

What the studies did not test

• Non-oral routes in humans. The keratinocyte and hydrogel studies were laboratory and animal experiments, not human trials of topical or injected larazotide (PMID 40330848, PMID 40915363).
• Healthy-population use. The randomized trials enrolled patients with celiac disease under defined dietary conditions, not people without disease seeking barrier or wellness effects (PMID 25683116, PMID 23163616).
• Long-term exposure. No verified paper reports multi-year dosing, and the meta-analysis pooled short randomized trials rather than long-term safety cohorts (PMID 34339872).
• Head-to-head comparisons. The literature does not compare larazotide against other permeability-directed candidates or against immune-directed celiac therapies in the verified set (PMID 33397225).
• Extrapolation across organs. Intestinal, hepatic and skin barrier findings came from separate models with separate endpoints (PMID 34791921, PMID 33886649).

Readers comparing these findings should keep model, endpoint and dose together: in this literature the three are inseparable, and a result reported in porcine tissue or a rat model is a laboratory observation, not a clinical outcome.

References

• Larazotide acetate: a pharmacological peptide approach to tight junction regulation (American Journal of Physiology: Gastrointestinal and Liver Physiology, 2021)
• Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide (Science Translational Medicine, 2025)
• Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment (Journal of Controlled Release, 2025)
• The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases (Current Medicinal Chemistry, 2021)
• Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials (Clinics and Research in Hepatology and Gastroenterology, 2022)
• Larazotide acetate regulates epithelial tight junctions in vitro and in vivo (Peptides, 2012)
• Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions (PLoS One, 2021)
• The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate (Therapeutic Advances in Gastroenterology, 2016)
• Effects of larazotide acetate, a tight junction regulator, on the liver and intestinal damage in acute liver failure in rats (Human & Experimental Toxicology, 2021)
• Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial (Gastroenterology, 2015)
• The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes (JID Innovations, 2025)
• Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study (Alimentary Pharmacology & Therapeutics, 2013)